Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.
Barriers to management of HCV in injection drug users are related to patients, health providers, and facilities. In a primary care drug user's addiction centre we studied access to HCV standard of care before and after using an onsite total care concept provided by a multidisciplinary team and noninvasive liver fibrosis evaluation. A total of 586 patients were seen between 2002 and 2004. The majority, 417 patients, were HCV positive and of these patients 337 were tested positive for HCV RNA. In 2002, patients were sent to the hospital. with the Starting of 2003, patients were offered standard of care HCV management in the center by a team of general practitioners, a consultant hepatologist, psychiatrists, nurses, and a health counsellor. Liver fibrosis was assessed by a non invasive method. In 2002, 6 patients had liver fibrosis assessment at hospital facilities, 4 patients were assessed with liver biopsy and 2 patients with Fibrotest-Actitest. 2 patients were treated for HCV at hospital. In 2003 and 2004, 224 patients were assessed with Fibrotest-Actitest on site. Of these, 85 were treated for HCV. SVR was achieved in 43%. We conclude that the combination of an onsite multidisciplinary team with the use of a noninvasive assessment method led to improved management of HCV infection in drug users' primary care facility.
Moussalli
Joseph
J
Service d'hépatologie, Université Pierre et Marie Curie Liver Center, Hôpital La Pitié Salpêtrière, 75013 Paris, France.
Delaquaize
Helene
H
Boubilley
Dominique
D
Lhomme
Jean Pierre
JP
Merleau Ponty
Jules
J
Sabot
David
D
Kerever
Anne
A
Valleur
Marc
M
Poynard
Thierry
T
Drug Alcohol Depend. 2002 Jul 1;67(2):117-23
12095661
Eur J Gastroenterol Hepatol. 2006 Feb;18(2):159-66
16394797
Hepatology. 2004 Jul;40(1):120-4
15239094
J Viral Hepat. 2002 Jan;9(1):62-70
11851904
Hepatology. 2003 Feb;37(2):443-51
12540795
Hepatology. 2007 Oct;46(4):991-8
17668880
Eur Addict Res. 2007;13(4):216-21
17851243
J Subst Abuse Treat. 2005 Oct;29(3):159-65
16183464
Addiction. 2007 Mar;102(3):423-31
17298650
Hepatology. 2002 Nov;36(5 Suppl 1):S210-9
12407596
Hepatology. 2007 Jan;45(1):111-7
17187435
J Community Health. 2008 Jun;33(3):126-33
18165889
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S325-9
15768342
Am J Gastroenterol. 2003 Oct;98(10):2281-8
14572580
J Gastroenterol Hepatol. 2007 Sep;22(9):1519-25
17645460
Hepatology. 2001 Jul;34(1):188-93
11431750
Drug Alcohol Depend. 2008 Jan 11;93(1-2):141-7
17997050
Clin Ther. 2002 Oct;24(10):1627-35
12462291
Int J Drug Policy. 2007 Oct;18(5):437-43
17854734
Lancet. 2001 Sep 22;358(9286):958-65
11583749
AIDS. 2006 Nov 28;20(18):2361-9
17117023
J Hepatol. 1997 Apr;26(4):794-7
9126791
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
Epidemiol Infect. 2005 Apr;133(2):305-14
15816156
Hepatology. 2002 Nov;36(5 Suppl 1):S35-46
12407575
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S336-8
15768344
Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B138-43
12180281